[Blood coagulation and fibrinolysis in women receiving estrogen, gestagen and estrogen-gestagen-contraceptives (author's transl)]

Abstract

Eight femal subjects received a contraceptive with a low estrogen content (Neogynon), the estrogen component (50 mug ethinylestradiol) and consecutively the gestagen component (250 mug D-Norgestrel) of the contraceptive. Each treatment cycle was followed by a control cycle. At various times of the control and therapy cycles several coagulation and fibrinolytic parameters were investigated. Statistical analyses were performed by multivariate two-factorial analysis of variance. Plasminogen exhibities a statistically significant increase during the treatment with ethinylestradiol and the combination of this steroid with D-norgestrel. No significant changes were found for all other parameters, including partial thromboplastin time, fibriogen, factors X, IX, VIII, factor VIII-related antigen, antithrombin III and fibrin(ogen)degradation products.

PIP: The effects of a contraceptive with a low estrogen content (Neogynon), the estrogen component (50 mcg ethinyl estradiol) and consecutively the gestagen component (250 mcg D-Norgestrel) of the contraceptive on blood coagulation and fibrinolysis were studied in 8 women. Each treatment cycle was followed by a control cylce. At various times of the control and therapy cycles coagulation and fibrinolytic parameters were investigated. Statistical analyses were performed using multivariate 2-factorial analysis of variance. Plasminogen exhibited a statistically significant increase during the treatment with ethinyl estradiol and the combination of this steroid with D-norgestrel. No significant changes were found for all other parameters, including partial thromboplastin time, fibrinogen, Factors X, IX, VIII, Factor VIII-related antigen, antithrombin III, and fibrin(ogen)degradation products.